Ménière’s disease may begin early in inner ear development
A Penn Medicine study shows the first clear biological roadmap for a poorly understood inner ear disorder.
2 min. read
By analyzing genetic data from nearly 2 million people, researchers have unlocked a new scientific understanding of Ménière’s disease, a chronic and often debilitating inner ear disorder. A team from the Perelman School of Medicine has found evidence that the condition may be linked in part to how the inner ear develops early in life—rather than being caused solely by problems that arise in adulthood, as previously thought. The findings are published in the American Journal of Human Genetics.
Ménière’s disease affects about 1 in 2,000 people and is characterized by episodes of vertigo, fluctuating hearing loss, tinnitus—a ringing, buzzing, clicking, or hissing sound in the ear when no external sound is present—and a feeling of fullness in the ear. While the condition has long been associated with abnormal fluid buildup in the inner ear, its underlying causes have remained poorly understood. This new research provides the first large-scale genetic framework for the disease and points to biological pathways that may help explain both its origins and its symptoms.
“Our findings suggest that Ménière’s disease is not just something that arises from fluid imbalance later in life,” says Douglas Epstein, a professor and vice chair of genetics and senior co-author of the study. “Instead, it may begin with subtle differences in how the inner ear is built in the first place. These differences are usually small and within the normal range, but they may make some people more vulnerable to problems decades later.”
In addition to developmental genes, the study highlights the importance of a biological pathway involving retinoic acid, a molecule derived from vitamin A that helps regulate organ development and fluid balance. The researchers found signals near genes that control retinoic acid levels, suggesting this pathway may play a role in how the inner ear maintains proper pressure and fluid dynamics. This finding helps connect longstanding theories about fluid imbalance with new insights into developmental biology.
“This gives us a much clearer starting point,” says Bogdan Pasaniuc, a professor of genetics and senior co-author of the study. “For a long time, Ménière’s disease has been difficult to study because we didn’t know what biological systems to focus on. Now we have strong evidence pointing to specific pathways that matter.”
The study also finds that Ménière’s disease shares genetic connections with related conditions such as hearing loss, tinnitus, vertigo, migraine, and sleep apnea, suggesting that these disorders may have overlapping biological roots.
When the Schuylkill swallowed the city: Lessons from Hurricane Ida’s historic flood
New Penn research shows that Hurricane Ida wasn’t a once-in-a-century anomaly but a preview of how climate change, urbanization, and aging infrastructure are rewriting flood risk.
The Fed explained: What it does and why it matters
Former Philadelphia Fed President Patrick Harker and financial historian Peter Conti-Brown, both Wharton professors, unpack the central bank’s origins, its unusual structure, and the quiet ways it shapes the economy
How population changes are impacting primary education worldwide
Research from Penn sociologist Emily Hannum and colleagues reveals regional trends in whether school-age populations are increasing, plateauing, or decreasing—and shows how different countries are responding.
A bioengineered bean gum from the lab of Penn Dental’s Henry Daniell is found to reduce the levels of three microbes associated with head and neck squamous cell cancer to almost zero, without affecting the beneficial bacteria normally found in the mouth.
Fighting oral cancer with bioengineered chewing gum
Research led by Penn Dental’s Henry Daniell shows that antiviral and antibacterial chewing gums reduce the levels of three microbes linked to worse outcomes in oral cancers, paving the way for more effective and affordable therapies.
